Key Takeaways MCK posted strong Q3 results with growth in specialty distribution, oncology services, and biopharma solutionsMCK saw 11% revenue growth and a 37% surge in oncology and multispecialty sales from expansion and buyout.MCK faces margin pressure in core distribution and weak Medical-Surgical performance with profit down 10%.McKesson (MCK) reported strong third-quarter fiscal 2026 results, driven by robust growth in specialty distribution, oncology services and biopharma solutions. Continued operat ...